Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Amortization of Deferred Charges (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Amortization of Deferred Charges for 4 consecutive years, with -$1.7 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Amortization of Deferred Charges fell 197.35% year-over-year to -$1.7 million, compared with a TTM value of -$5.2 million through Dec 2023, down 6535.8%, and an annual FY2024 reading of -$2.1 million, up 59.91% over the prior year.
  • Amortization of Deferred Charges was -$1.7 million for Q4 2023 at Terns Pharmaceuticals, up from -$1.7 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $613000.0 in Q1 2022 and bottomed at -$1.7 million in Q3 2023.
  • Average Amortization of Deferred Charges over 4 years is -$324307.7, with a median of -$3000.0 recorded in 2021.
  • The sharpest move saw Amortization of Deferred Charges skyrocketed 20533.33% in 2022, then tumbled 6626.92% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $37000.0 in 2020, then soared by 424.32% to $194000.0 in 2021, then tumbled by 391.75% to -$566000.0 in 2022, then crashed by 197.35% to -$1.7 million in 2023.
  • Business Quant data shows Amortization of Deferred Charges for TERN at -$1.7 million in Q4 2023, -$1.7 million in Q3 2023, and -$975000.0 in Q2 2023.